Free Trial

KalVista Pharmaceuticals (KALV) Competitors

KalVista Pharmaceuticals logo
$11.13 +0.13 (+1.18%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$11.12 -0.01 (-0.09%)
As of 10/24/2025 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KALV vs. SRPT, ETNB, MESO, OCUL, ANIP, VERA, COGT, STOK, VCEL, and RCUS

Should you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Sarepta Therapeutics (SRPT), 89BIO (ETNB), Mesoblast (MESO), Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Cogent Biosciences (COGT), Stoke Therapeutics (STOK), Vericel (VCEL), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.

KalVista Pharmaceuticals vs. Its Competitors

Sarepta Therapeutics (NASDAQ:SRPT) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

In the previous week, Sarepta Therapeutics had 5 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 6 mentions for Sarepta Therapeutics and 1 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 1.91 beat Sarepta Therapeutics' score of 0.95 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Sarepta Therapeutics Positive
KalVista Pharmaceuticals Very Positive

KalVista Pharmaceuticals has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.34%. Sarepta Therapeutics' return on equity of -1.03% beat KalVista Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Sarepta Therapeutics-2.34% -1.03% -0.37%
KalVista Pharmaceuticals N/A -212.79%-97.85%

Sarepta Therapeutics has higher revenue and earnings than KalVista Pharmaceuticals. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$1.90B1.17$235.24M-$0.87-26.22
KalVista Pharmaceuticals$1.43M394.33-$183.44M-$3.94-2.82

Sarepta Therapeutics currently has a consensus price target of $34.46, suggesting a potential upside of 51.07%. KalVista Pharmaceuticals has a consensus price target of $26.43, suggesting a potential upside of 137.45%. Given KalVista Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe KalVista Pharmaceuticals is more favorable than Sarepta Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sarepta Therapeutics
7 Sell rating(s)
14 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.03
KalVista Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.90

Sarepta Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of -0.15, suggesting that its stock price is 115% less volatile than the S&P 500.

86.7% of Sarepta Therapeutics shares are held by institutional investors. 7.6% of Sarepta Therapeutics shares are held by insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Sarepta Therapeutics beats KalVista Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get KalVista Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KALV vs. The Competition

MetricKalVista PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$555.75M$3.02B$6.24B$10.67B
Dividend YieldN/A57.75%5.72%4.81%
P/E Ratio-2.8227.5331.1930.71
Price / Sales394.33613.11560.36173.93
Price / CashN/A168.3237.0861.44
Price / Book5.805.6512.056.61
Net Income-$183.44M$33.06M$3.33B$277.10M
7 Day Performance0.27%3.16%1.93%2.56%
1 Month Performance-8.02%8.14%7.77%3.77%
1 Year Performance-4.71%-2.49%56.40%33.01%

KalVista Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KALV
KalVista Pharmaceuticals
3.8117 of 5 stars
$11.13
+1.2%
$26.43
+137.5%
-7.8%$555.75M$1.43M-2.82100Analyst Forecast
SRPT
Sarepta Therapeutics
4.544 of 5 stars
$23.05
+2.4%
$34.42
+49.3%
-82.7%$2.20B$1.90B-26.491,372Analyst Forecast
ETNB
89BIO
2.8671 of 5 stars
$14.80
+0.3%
$25.81
+74.4%
+90.3%$2.19BN/A-4.1040News Coverage
Analyst Forecast
Short Interest ↓
MESO
Mesoblast
1.9725 of 5 stars
$17.65
+3.4%
$24.00
+36.0%
+93.9%$2.18B$17.20M0.0080Analyst Forecast
OCUL
Ocular Therapeutix
4.3202 of 5 stars
$12.18
+2.9%
$22.63
+85.8%
+5.5%$2.06B$63.72M-9.52230Positive News
Analyst Forecast
ANIP
ANI Pharmaceuticals
3.8842 of 5 stars
$95.12
+0.3%
$99.14
+4.2%
+59.0%$2.06B$614.38M-123.53600News Coverage
Positive News
Analyst Upgrade
VERA
Vera Therapeutics
2.7128 of 5 stars
$30.20
-3.3%
$61.50
+103.6%
-26.6%$1.99BN/A-8.4440News Coverage
Analyst Forecast
COGT
Cogent Biosciences
2.3071 of 5 stars
$16.22
-1.0%
$19.67
+21.2%
+26.0%$1.87BN/A-9.1180News Coverage
Analyst Forecast
STOK
Stoke Therapeutics
3.2784 of 5 stars
$34.65
+3.3%
$30.83
-11.0%
+167.9%$1.84B$36.56M40.77100Analyst Forecast
Gap Up
VCEL
Vericel
3.4507 of 5 stars
$36.02
+2.0%
$58.40
+62.1%
-15.3%$1.78B$237.22M300.19300Analyst Forecast
RCUS
Arcus Biosciences
2.7733 of 5 stars
$17.47
+6.1%
$27.22
+55.8%
-2.9%$1.75B$258M-5.51500Analyst Forecast
Gap Up

Related Companies and Tools


This page (NASDAQ:KALV) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners